Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01587690 · ClinicalTrials.gov registry record

Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells

A clinical trial, sponsored by Rutgers, The State University of New Jersey.

Completed
Registry status
24
Enrollment target

NCT01587690 is a clinical trial that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01587690 has completed, sponsored by Rutgers, The State University of New Jersey.

COMPLETED
Registry status
24 participants
Enrollment target

Study Summary

MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported in many human diseases. The purpose of this pilot study is to determine if microRNA expression is changed in untreated and interferon-beta-treated patients with multiple sclerosis.

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2011-11
Est. Completion 2013-01

What the Registry Record Tells You About NCT01587690

The ClinicalTrials.gov registry entry for NCT01587690 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01587690 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01587690 about?

NCT01587690 is a clinical study titled "Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells". MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported in many human diseases. The purpose of this pilot study is to determine if microRNA expression is changed in untreated and interferon-beta-treated patients with multiple sclerosis.

What is the current status of trial NCT01587690?

This trial is currently completed. The enrollment target is 24 participants. The study started on 2011-11. Estimated completion is 2013-01.

Who is sponsoring clinical trial NCT01587690?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.